降糖药物与接受膀胱内卡介苗免疫治疗的NMIBC患者长期生存结局之间的关联
该研究基于香港全地区数据库,纳入2001至2020年接受膀胱内卡介苗治疗的2602例NMIBC患者,其中19.5%在BCG开始时使用降糖药,80.5%未使用。中位随访11年,Kaplan-Meier分析显示两组总生存有显著差异(p<0.01),但癌症特异性生存、无复发生存和无进展生存无显著差异。多因素Cox回归显示以二甲双胍为基础的降糖治疗是无复发生存的独立危险因素(HR 1.22,95%CI 1.02-1.46)。
要点
- 在BCG治疗的NMIBC患者中,19.5%在BCG开始时使用降糖药,80.5%未使用。
- 中位随访11年,总生存两组差异显著(p<0.01),但癌症特异性生存、无复发生存和无进展生存无显著差异。
- 以二甲双胍为基础的降糖治疗是无复发生存的独立危险因素(HR 1.22,95%CI 1.02-1.46)。
核心结论
- 以二甲双胍为基础的降糖治疗是接受BCG治疗的NMIBC患者无复发生存的独立危险因素。
- 使用非二甲双胍类降糖药物与长期生存结局无关。
研究设计与样本
- 研究基于香港全地区数据库,纳入2001至2020年接受膀胱内BCG治疗的NMIBC患者。
- 共纳入2602例患者,根据BCG治疗开始时是否使用降糖药分为两组:治疗组507例(19.5%),对照组2095例(80.5%)。
- 采用Kaplan-Meier法分析总生存、癌症特异性生存、无复发生存和无进展生存,多因素Cox回归校正混杂因素并估计HR和95%CI。
- 进行亚组分析评估二甲双胍对生存结局的特定影响。
主要发现
- 中位随访11年,Kaplan-Meier分析显示两组总生存差异显著(p<0.01),但癌症特异性生存(p=0.36)、无复发生存(p=0.19)和无进展生存(p=0.05)无显著差异。
- 亚组分析比较二甲双胍组、非二甲双胍降糖药组和对照组,显示总生存(p<0.01)和无复发生存(p=0.02)差异显著,但癌症特异性生存(p=0.59)和无进展生存(p=0.08)无显著差异。
- 多因素Cox回归分析显示,以二甲双胍为基础的降糖治疗是无复发生存的独立危险因素(HR 1.22,95%CI 1.02-1.46)。
- 非二甲双胍类降糖药物与无复发生存无显著关联(HR 0.71,95%CI 0.47-1.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is a lack of data on the impact of hypoglycemia agents, especially metformin, on prognosis for non-muscle-invasive bladder cancer (NMIBC). Our aim was to investigate the association between hypoglycemia agents, especially metformin, and long-term survival outcomes for patients with NMIBC treated with bacillus Calmette-Guérin. METHODS: All patients with NMIBC treated with intravesical BCG therapy from 2001 to 2020 were identified in a territory-wide database in Hong Kong. Patients were stratified into two groups according to whether or not they were taking a hypoglycemia agent at BCG treatment initiation. We analyzed data for overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) using the Kaplan-Meier method. Multivariable Cox regression analysis was used to adjust for potential confounding factors and estimate hazard ratio (HRs) and 95% confidence intervals (CIs). Subgroup analyses were conducted to assess the specific influence of metformin on survival outcomes. KEY FINDINGS AND LIMITATIONS: Of 2602 patients with NMIBC treated with intravesical BCG, 19.5% (n = 507) were taking a hypoglycemia agent at BCG initiation (treatment group) and 80.5% (n = 2095) were not (control group). At median follow-up of 11 yr, Kaplan-Meier analysis revealed a significant difference in OS between the groups (p < 0.01), but not in CSS (p = 0.36), RFS (p = 0.19), or PFS (p = 0.05). Subgroup analysis comparing outcomes for patients taking metformin, patients taking a hypoglycemia agent other than metformin, and control subjects revealed significant differences in OS (p < 0.01) and RFS (p = 0.02), but not in CSS (p = 0.59) or PFS (p = 0.08). Multivariable Cox regression analysis identified metformin-based treatment for hypoglycemia as an independent risk factor for RFS (HR 1.22, 95% CI 1.02-1.46), whereas hypoglycemia agents other than metformin were not significantly associated with RFS (HR 0.71, 95% CI 0.47-1.06). CONCLUSIONS AND CLINICAL IMPLICATIONS: Metformin-based hypoglycemia treatment was an independent risk factor for RFS in BCG-treated NMIBC. Hypoglycemia treatment with an agent other than metformin was not related to long-term survival outcomes. PATIENT SUMMARY: We investigated the relationship between treatment for high blood sugar and long-term survival for patients with intermediate-risk or high-risk non-muscle-invasive bladder cancer. The patients had received BCG (bacillus Calmette-Guérin) treatment in Hong Kong for their bladder cancer over the past two decades. Our results show that metformin, but not other drugs used to treat high blood sugar, was associated with poorer survival free from bladder cancer recurrence for these patients.
引用
- Liu K, Zhao H, Chen X, et al. Association Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guérin Immunotherapy. Eur Urol Oncol. 2024. PMID: 39689991. doi:10.1016/j.euo.2024.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。